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Borna disease (BD), first described more
than 200 years ago in southern Germany as a
fatal neurologic disease of horses and sheep, owes
its name to the town Borna in Saxony, Germany,
where a large number of horses died during an
epidemic in 1885. The virus etiology of BD was
proven in the early 1900s when Zwick and co-
workers (1) in Giessen, Germany, successfully
transmitted brain homogenates from infected
horses to experimental animals. Other milestones
in BD-related research were the demonstration
of virus growth in cell cultures (2-4); the finding
that the pathogenesis of BD is caused by a T-cell–
dependent immune mechanism (5-8); and most
recently, the molecular characterization of the
etiologic agent of BD, the highly neurotropic
Borna disease virus (BDV) (9-17).
BD is characterized by a disseminated
nonpurulent meningoencephalomyelitis with infil-
tration of mononuclear cells (1,8,18,19) and a
predilection for the gray matter of the cerebral
hemispheres and the brain stem (8,19). In neu-
rons, sometimes in glia cells, acidophilic intra-
nuclear inclusion bodies, called Joest-Degen inclu-
sion  bodies, are occasionally found. BD occurs
sporadically in Germany and Switzerland; its
presence in other countries has not yet been
substantiated. Natural infections in other Equidae,
ruminants, rabbits, cats, and ostriches have also
been described (19-21).
This review discusses the etiology of Borna
disease, the natural and experimental infection
in various animal species, the pathogenesis of
the disease in the experimental rat model, the
genetic stability of BDV, and the possible link
between BDV or a similar agent and human
neuropsychiatric disorders.
Etiology
The etiologic agent of BD, BDV, has been
recently characterized as an enveloped, non-
segmented, negative-stranded RNA virus with a
genomic size of approximately 9 kb and a nuclear
site for replication and transcription (14-17). The
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genomic organization is similar to that of mem-
bers of the Mononegavirales order; therefore,
BDV is the prototype of the new family
Bornaviridae within this order. The Mono-
negavirales also include Filoviridae (e.g., Marburg
and Ebola viruses), Paramyxoviridae (e.g.,
mumps, measles virus), and Rhabdoviridae (e.g.,
rabies, vesicular stomatitis virus). Six major
open reading frames (ORFs)(I,II,III, IV,V,x1) are
predicted in the genome sequence (16,17). Only
five ORFs correspond to previously identified
proteins with molecular weights of 10 (ORF x1:
p10 BDV gene; 22), 18 (ORF III: gp18 BDV gene;
23), 24 (ORF II: p24 BDV gene; 24), 38/39 (ORF I:
p38 BDV gene; 25), and 94 (ORF IV: p57 BDV
gene; 26) or 84 (ORF IV: p57 BDV gene; 27, Richt
et al., unpub. obs.) kDa.
Natural and Experimental Infection
Natural Infection
Extensive epizootiologic studies in horses
have shown that BD is rare but occurs all over
Germany, extending beyond the classic disease-
endemic regions (28-30). Furthermore, BDV-
specific antibodies were detected in horses in
several European countries, Israel (28,29), Japan
(31), Iran (32), and the United States (33). Since
BDV-specific antibodies are frequently found in
clinically healthy horses (20,28,29), natural infec-
tions in horses seem to remain subclinical in most
cases. Unknown exogenous and endogenous fac-
tors might influence the genesis of the disease (20).
In addition to its predominant natural host,
the horse, other Equidae, sheep, cattle, rabbits,
goats, deer, alpacas, llamas, cats, pigmy hippo-
potamus, sloth, vari monkeys (memur variegatus),
and ostriches have become naturally infected
with BDV (8,19,20,34,35). In sheep flocks,
clinical BD can affect large numbers of animals;
however, in horse stables, usually only a few
animals show clinical signs. The virus is assumed
to be transmitted through salival, nasal, or
conjunctival secretions because BDV-specific
RNA has been found in these secretions
(20,28,29,36). Animals become infected by direct
contact with these secretions or by exposure to
contaminated food or water. A minimum incu-
bation period of 4 weeks is estimated for horses
and sheep with nonspecific signs such as hyper-
thermia, anorexia, colic, and constipation in the
initial phase of the disease. During the acute
phase of disease, neurologic signs such as ataxia,
depression, circular movement, standing in awk-
ward positions, collapsing, running into obstacles,
and paralysis, result from nonpurulent menin-
goencephalomyelitis. Clinical illness usually lasts 1 to
3 weeks, and death rates for diseased horses are
80% to 100% (18-20,37). In surviving animals,
recurrent episodes are possible, especially after
stress (18). Clinical manifestations, however, may
vary among individual animals and various species.
BD tends to occur in spring and early summer
and is more frequent in some years than in
others; therefore, arthropods have been discussed
as a potential vector. BDV, however, has never
been isolated from insects in Europe. In the Near
East, ticks have been associated with transmission
of an equine encephalomyelitis similar to BD
(38). A definite virus reservoir for BDV has not
been found; various rodents most likely represent
such a reservoir. In addition, since many sero-
positive horses with subclinical infections have
infectious virus or BDV-specific RNA in various
secretions, they can be potential sources of
infection for other animals and humans (29,36).
Experimental Infection
BDV can be experimentally transmitted to a
wide variety of animal species, from chickens to
nonhuman primates (1,8,19,20,37). Incubation
periods, clinical signs, and severity of the disease
depend on the animal species and the virus
variants. Rabbits, Lewis rats, and guinea pigs
are highly susceptible, whereas chickens,
monkeys, cattle, and tree shrews (Tupaia glis;39)
are less susceptible (8,19). Some animals (ham-
sters, black-hooded rats, mice, ferrets, pigeons,
and dogs), however, do not develop disease
despite being persistently infected with BDV
(1,8,18,19). The pathohistologic picture after
experimental infections resembles that of
natural infections. Most experimentally infected
animals develop perivascular and parenchymal
central nervous system (CNS) infiltrations and
have infectious virus in the brain tissue.
Frequently, the clinical picture in experimentally
infected animals does not differ from that of
spontaneously infected natural hosts.
The result of BDV infection in rats depends
on the inbred rat strain and the virus isolate used
for infection. Black-hooded rats do not show
clinical signs after BDV infection with BDV
isolates despite persistent virus infection and
mononuclear infiltration of the CNS (40). Lewis
rats, however, are highly susceptible and are345 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
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therefore used extensively for studies of BD
pathogenesis (see below; 5,8,19). When infected
with various BDV variants, Lewis rats exhibited
clinical manifestations such as behavioral dis-
orders, paralytic disease, or obesity, in addi-
tion to fertility problems (8,19), which indi-
cates that BDV can form virus variants with
different biologic properties.
Pathogenesis
BDV is a highly neurotropic agent that gains
access to the CNS, probably by intraaxonal
migration through the olfactory nerve or nerve
endings in the oropharyngeal and intestinal
regions (18,41). Virus spreads throughout the
CNS by intraaxonal transport and centrifugally
into the peripheral nerves. Antibody titers in
naturally infected animals, such as in horses
with clinical BD, are relatively low and are found
in sera and cerebrospinal fluid (CSF) (19,20,28,29).
Whether BDV-specific antibodies are neutralizing
is not certain (5,42); the coexistence of BDV-
specific antibodies and infectious virus in the
CSF contradicts this assumption (43).
Extensive studies in the Lewis rat showed
that the immune response to viral antigens after
BDV infection does not elicit protective immunity
but rather an immunopathologic reaction in
which T cells play an important role (5,44). After
adult rats are infected intra-cerebrally or
intranasally, productive virus replication is
found in the entire CNS. Once introduced into the
rat’s CNS, BDV usually causes a persistent
infection with continuous productive replication
in the brain and spinal cord (5,8). In
immunocompetent animals, no infectivity was
found in extraneural tissues at any stage of
infection (5,45). In newborn animals, in contrast,
the virus spreads throughout the whole
organism; BDV-specific antigen was found in
parenchymal cells of numerous organs, and
infectious virus was found in excretions (45). The
age of rats at the time of infection affects the
capacity of host cells to support virus replication
and, therefore, to control the spread of BDV.
The reason for the variation in virus repli-
cation is still unclear, and differences in the host’s
immunocompetence cannot be the only factor,
since in adult immunosuppressed rats the virus
is strictly neurotropic (45). All immunocompetent
animals develop antibodies to BDV-specific anti-
gens, and these antibodies coexist with infectious
virus in the CNS (5). The outcome of BDV
infections in rats depends on the rat strain and the
passage history of the virus (see above; 19,40).
Despite productive virus replication in the
CNS, immunocompromised animals (immuno-
logically incompetent newborn and athymic rats)
and immunosuppressed (by cyclophosphamide or
cyclosporine A) animals do not become ill with
BD or encephalitis, as do immunocompetent
animals (5-8,29,44,46,47). The hypothesis of a
virus-induced cell-mediated immunopathologic
basis of BD was confirmed in adoptive transfer
experiments in which spleen cells from infected
rats were transferred into immunosuppressed
virus carriers (5). Recipient rats developed BDV-
specific antibodies, encephalitis and disease (5).
The critical role of T cells in the pathogenesis of
BD was demonstrated in adoptive transfer
experiments: transfer of BDV-specific major
histocompatibility complex class II-restricted
TH1 cell lines into drug-tolerized virus carriers
resulted in acute meningoencephalitis and
disease (Table 1; 6-8,29,47).
Consequently, conventional immunization
with inactivated virus preparations or purified
virus-specific antigens did not confer protective
immunity against clinical BD, despite detectable
levels of virus-specific antibodies after immuni-
zation (25; Richt, unpub. data). However, when
viable BDV-specific TH1 cells were passively
transferred into naive rats before virus infection,
animals were protected against clinical BD after
challenge (Table 1; 29,47,48, Schmeel et al.,
unpub. obs.). In contrast, injection of the same
viable BDV-specific TH1 cells after BDV-infection
induced clinical disease faster in BDV-uninfected
animals than in BDV-infected control animals
(29,47,48, Schmeel et al., unpub. obs.). Thus, in
Table 1. Adoptive transfer of Borna disease virus (BDV)
TH1 cells before and after BDV infection
CY Transfer of Clinical
Group treatment TH1-cells BD
Control yes       day +10  no
BDV yes           no  no
BDV  no       day +10 yes
BDV yes        day +3 yes
BDV yes       day +10 yes
BDV  no  day -25 and -5  no
Four-week-old Lewis rats were inoculated intracerebrally
with BDV; some rats were treated with cyclophosphamide
(CY) (150 mg/kg) for immunosuppression 24 hours later.
Animals were intravenously injected with >2x106 BDV  TH1
cells on the indicated days, either before (-) or after (+)
infection with BDV.346 Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997
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BDV infections of the CNS with immunopathologic
lesions, the same virus-specific immune cells
that cause disease can also prevent disease,
depending on the dynamics of virus replication at
the time of the T-cell response.
Several reports of the pathogenesis of BD in
BDV-infected animals indicate that the patho-
genesis of BD in naturally and experimentally
infected animals is also immunopathologic since
the pathohistologic picture, including CNS-
infiltrating cells in naturally BDV-infected ani-
mals, resembles that of experimentally infected
rats (19); and immunosuppression or splenec-
tomy of experimentally BDV-infected rabbits
(49) and splenectomy of BDV-infected monkeys
(Macaca mulatta; 50) affected the severity of
clinical signs or prevented disease.
BDV Isolates from Naturally
Infected Horses
To study the genetic variability of BDV, virus
isolates were derived from three clinically ill
horses in Germany (Lower Saxony, Rhineland-
Palatina, Bavaria), euthanized between 1989
and 1995. BDV-specific antibodies were detected
in the serum, and infectious virus, viral proteins,
and viral RNA were detected in the CNS of all
three horses (Pfeuffer et al., unpub. obs., 51).
Molecular analysis of five different ORFs was
performed. The coding regions of ORFs I, II, III,
IV, and x1 were amplified by the reverse
transcriptase-polymerase chain reaction (RT-
PCR) technique with total RNA isolated from the
CNS (36); the amplified cDNA was cloned and
sequenced. The sequences of the respective ORFs
were aligned and compared with viral sequences
derived from a cell-culture–adapted virus strain,
BDV strain V (14), which was isolated in 1929
from a horse with clinical BD. In the analyzed
clones, two deletions resembling post-
transcriptionally spliced mRNA species were
identified (Pfeuffer et al., unpub. obs., 51).
Similarly, two introns were recently identified
when cell-culture–adapted BDV isolates were
molecularly analyzed (16,17).
The degree of homology between the
analyzed BDV isolates and the reference BDV
strain V isolated more than 60 years ago (14) for
the p24 BDV gene is summarized in Table 2.
There is a maximal divergence of 2.0% at the
nucleotide level and 2.5% at the amino acid level
(Table 2). These data agree with recently
published observations showing a high degree of
homology within the p24 BDV gene of wild-type and
cell-adapted viruses (52,53). When the other four
ORFs were similarly analyzed, a homology of >95%
at the nucleotide level and >97% at the amino acid
level was found (Pfeuffer et al., unpub. obs., 51),
indicating that in addition to the previously
analyzed p24 (ORF II; 52,53) and p38 (ORF I; 53)
genes, the other BDV-ORFs (ORFs III, IV, x1) also
exhibit high genetic stability within one host
species, the horse (Pfeuffer et al., unpub. obs., 51).
Nevertheless, antigenic variations of BDV
wild-type isolates were found when brain
material from approximately 50 horses with BDV
infections were screened by immunocytochemistry
and immunoblot assays with BDV-specific
monoclonal and monospecific antibodies (51).
Two isolates (horse #215, horse #2,300) showed a
remarkable difference in antigenicity (Figure
1A,B). These isolates were not recognized by the
p38 specific monoclonal antibody (mAb) Bo18
(25,51; Figure 1A). Polyclonal reconvalescent
(51) and monospecific p38 antiserum or mono-
specific p24 antiserum (Figure 1B), however,
reacted with BDV-specific proteins from both
isolates in immunocytochemistry assays (Figure
1B) and immunoblots (51), indicating that the
p38 and p24 BDV-proteins were synthesized. The
recognition site for the mAb Bo18 within the p38
BDV-protein, however, was altered. To obtain
detailed information on the location of these
changes, we cloned and analyzed the p38 BDV
gene of two horse isolates. Sequence analysis
showed several nucleotide mutations within the
respective p38 BDV genes; only one, however,
led to an amino acid replacement (51). The
Table 2. Percentage of p24 Borna disease virus gene
sequence homology
Strain Horse Horse Horse
V #215 #640 #2300
Strain V 99.0 97.5   99.0
Horse#215 98.7 98.5 100.0
Horse#640 98.0 98.2 98.5
Horse#2300 98.8 98.7   98.2
Numbers above  diagonal are %homology at the amino acid
level; numbers below diagonal represent the %homology among
nucleotides. Strain V: isolated 1929 from a horse with clinical
BD from Lower Saxony. Horse #215: isolated 1989 from a horse
with clinical BD from Rhineland Palatine. Horse #640: isolated
1993 from a horse with clinical BD from Lower Saxony. Horse
#2300: isolated 1995 from a horse with clinical BD from347 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
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amino acid replacements were adjacent to each
other within the N-terminal part of the p38
protein, indicating that they are within the
epitope of mAb Bo18 (51).
BDV and Human Neuropsychiatric
Disorders
BDV’s wide host range and its association
with behavioral abnormalities in many species
such as rhesus macaques (1,50), tree shrews
(Tupaia glis; 39), and rats (5,8) suggest that BDV
may be involved in human neuropsychiatric
illnesses. Seroepidemiologic studies have
demonstrated BDV-specific antibodies in sera of
psychiatric and neurologic patients in Germany,
Japan, and the United States (13,51,54-71).
Recent studies with many patients showed a
significantly higher prevalence of BDV serum
antibodies among hospitalized psychiatric
patients and a moderately higher seropreva-
lence among neurologic patients than among
controls (13,56,60,68). Investigations of CSFs of
BDV-seropositive patients acutely ill with psy-
chiatric disorders (mainly schizophrenia and
affective psychoses) showed intrathecally syn-
thesized BDV-specific immunoglobulin (Ig) G in
25% of the patients (59).
A slightly higher level of seroprevalence was
found among psychiatric patients in an area with
high incidence of natural BD in horses (the BD-
endemic area around Günzburg in Southern
Germany) than among psychiatric patients in an
area without endemic BD in the United States
(Philadelphia area) (6.8% vs. 4.5%). The inci-
dence in healthy controls was considerably lower
in the United States (0% to 1%) than in the
Günzburg area (3% to 3.5%; 55). These studies
indicated a high number of clinically incon-
spicuous BDV-seropositive persons in the BD-
endemic area. Therefore, as is the case in horses,
inapparent BDV infections may be very com-
mon in humans (28,29,55).
An epidemiologic investigation of BDV
seroprevalence in a large number (n = 4,673) of
surgical (control), neurologic, and psychiatric
patients showed continuous age-dependent
increase in sero-prevalence in controls and
neurologic patients (Figure 2; 55); the dynamics
of seropositivity were different in psychiatric
patients. A twofold higher seroprevalence in
young neurologic patients paralleled a higher
prevalence in patients with acute or chronic
meningo-encephalitis and psychiatric disorders
(56,71). Seroprevalence among the youngest
quartile (aged 17-30 years) of psychiatric
patients was 600% higher than among surgical
patients (Figure 2;55), which suggests a role of
BDV  infections in the pathogenesis of
psychiatric disorders (psychiatric disorders
frequently begin in younger persons).
Initial investigations indicated a correlation
between BDV-specific antibodies and affective
psychoses (54,67). In a random group of psy-
chiatric patients, however, we found a similar
distribution of psychiatric disorders BDV-sero-
positive and BDV-seronegative patients
(psychiatric disorders and brain atrophy were
higher  among the more severely ill BDV-
seropositive patients [71]).
If a causal relationship exists between BDV
infections in naturally infected animals and BDV
seropositivity in humans, identifying patients
Figure 1. Immunohistologic analysis of consecutive brain
sections from the cerebral cortex of horse #215 with A)
the monoclonal antibody Bo18, specific for the p38/p39
BDV-protein and B) a rabbit monospecific serum, specific
for the p24 BDV-protein. Immunoreactive neurons are
only detected with the p24-specific antiserum. Papa-
nicolaou-counterstain, x130.
A
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with symptoms and disorder progression similar
to those of BDV-infected animals (paresis, weak-
ness of legs, excitability, or depression) would be
important. Recently, we identified a BDV-sero-
positive neurologic patient who exhibited abnor-
mal body postures, depressive and apathetic
behavior, and paresis (57). The patient worked at
his father’s farm, where one of four horses and
four of 10 sheep had antibodies specific for BDV
(57). The patient initially had a cerebral seizure
and later neurologic and psychiatric symptoms
resembling those of BD in animals and not
typical of other known human encephalitic dis-
orders, possibly implicating an acute, mild BDV
encephalitis. Although isolation and molecular
analysis of the respective viruses did not show an
infectious chain, BDV transmission from animals
to humans seems possible.
In addition, to study possible horizontal
transmission of BDV within families, we reviewed
the medical history of approximately 200 BDV-
seropositive neuropsychiatric patients for
coincident onset of mental or neurologic
disorders during 1 year within each family. Of
four families meeting the criteria, two were
studied in detail; both had neuropsychiatric
illness and BDV seropositivity in the primary
patient and also in a second family member in the
household (58). In two additional families, only
the primary patients, not the other psychiatrically
ill family members, showed BDV seropositivity
(58). In summary, humans can be infected by
BDV or a similar agent; a correlation between
BDV infection in animals and humans exists; and
BDV infections seem to contribute to or initiate
various psychiatric syndromes.
To verify the etiologic role of BDV in human
neuropsychiatric disorders, we tested specimens
from the CSF of more than 40 BDV-seropositive
neuropsychiatric patients for isolates of BDV or a
related agent. The CSFs were spread onto cell
cultures or injected intracerebrally into rabbits.
BDV or a related agent was detected in the CSF of
three neuropsychiatric patients (two patients
with acute lymphocytic meningoencephalitis,
one patient with acute schizophrenic psychosis;
67). The CSF of the schizophrenic patient showed
high amounts of BDV-specific IgG, which became
normal 5 years later when the CSF of this patient
was again analyzed during myelography before
lumbar surgery; at that time the patient was
mentally healthy (60). Injection of the respective
CSFs onto cell cultures showed expression of
BDV-specific antigens (by BDV-specific staining
pattern in an indirect immunofluorescence
assay). Expression of BDV antigen, however, was
lost, when these cells were passaged (13,67). In
addition, all three cerebrospinal fluids induced
BDV-specific antibodies in inoculated animals;
however, neither BDV replication nor BDV-
specific antigen was detected in the CNS of any
of these animals (13,67).
Most recently, de la Torre and co-workers
(72) detected both BDV-specific antigen and
BDV-RNA in four autopsied human brains with
hippocampal sclerosis and astrocytosis, which
confirms previous studies that BDV can infect
human brain tissue; whether BDV infection
contributes to the pathophysiology of human
neuropsychiatric disorders, however, warrants
further investigation.
Before this study, BDV-specific proteins (73),
BDV-specific RNA (63,64,69,74,75), and infectious
BDV (76) were found in peripheral blood mono-
nuclear cells of psychiatric patients. In addition,
the presence of BDV-RNA in these cells in 4% to
5% of Japanese blood donors was also reported
(63). Since these results have important impli-
cations for BD pathogenesis, the intra vitam
diagnosis, and the safety of blood and blood
products, we conducted a double-blind study of
BDV-specific markers in the blood of psychia-
tric  patients. Samples were aliquoted before
distribution to two different laboratories and
Figure 2. Borna disease virus seroprevalence among
different age groups.
Psych=psychiatric patients; Neuro=neurologic patients;
Surg=surgical (control) patients. Reproduced with
permission from Habilitationsschrift der Fakultät für
Klinische Medizin der Universität Ulm (55).
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tested independently. Forty-two seropositive
psychiatric patients and four seronegative
controls from a BD-endemic area in Germany
were analyzed. Consecutive samples obtained
over a 9-month period were included in the study.
The nested RT-PCR method was used with
primers specific for the p24 BDV-gene, the
internal primers identical to the one used by
Kishi and co-workers (63,64). Positive results for
BDV-specific RNA were obtained only in the
laboratory where BDV is routinely studied.
Simultaneous analysis of the samples in another
laboratory yielded negative results (62). In
addition, cocultivation of peripheral blood
mononuclear cells from 47 samples of seropositive
patients over two passages and from eight
samples over 8 to 10 passages with rabbit
embryonic brain cells did not provide evidence of
BDV or BDV-specific antigens (62). We thus
concluded that contami-nation can have a serious
influence on the out-come of studies using nested
RT-PCR methods to probe for BDV-specific
sequences in the peripheral blood mononuclear
cells of psychiatric patients.
Viral infections of the CNS are often difficult
to diagnose because conventional viral and sero-
logic laboratory methods are still unsatisfactory.
Existing standard techniques are either insen-
sitive and slow (virus culture) or highly
invasive and rare (brain biopsy) and, therefore,
are unsatisfactory as a measure for the accu-
racy of a new technique such as PCR or RT-PCR
(77). PCR techniques (PCR, RT-PCR, nested
PCR), with their speed and high molecular
sensitivity possess great potential for the
diagnosis of viral infections of the CNS.
To overcome the discrepancies of recent RT-
PCR studies about whether BDV or BDV-RNA
can be detected in the peripheral blood of humans
and animals, a multicenter study needs to be
conducted with an independent center responsible
for collecting and distributing samples to pre-
vent potential contamination by BDV-RNA.
These laboratories need to use similar RNA
isolation and RT-PCR techniques. Furthermore,
the  methods used by the laboratories conducting
sera or CSF analysis for BDV-specific anti-
bodies in animals and humans urgently need
further standardization.
Conclusion
Studies of the epizootiology and epidemiology
of BDV infections in the last decade underscore
the importance of BD as an emerging zoonosis.
Data clearly indicate that BDV or an analogous
virus can also infect humans. In addition to the
seroepidemiologic results, data from preliminary
studies on the isolation of BDV from the CSF and
the detection of BDV-specific antigen and BDV-
RNA in human brain confirm this conclusion.
Therefore, humans belong to the wide spectrum
of animal species, from birds to mammals, that
are susceptible to BDV infections.
The question of whether BDV infections in
humans contribute to human neuropsychiatric
disorders remains unsolved. A convincing argu-
ment might be the significantly increased BDV-
seroprevalence in psychiatric patients compared
with healthy controls. That some mentally or
neurologically healthy persons are BDV sero-
positive does not contradict this hypothesis, since
the natural infection in horses remains subclinical
in most cases and experimental intracerebral
application of BDV into highly susceptible ani-
mals does not always result in clinical disease
(Rott, pers. comm.). In addition, epizootiologic
studies suggest that BDV is not highly con-
tagious since only individual horses within a
stable succumb to clinical disease. Similarly,
analysis of a possible horizontal transmission of
BDV within family members and spouses of
approximately 200 BDV-seropositive neuro-
psychiatric patients showed only few cases of
coincident onset of mental or neurologic dis-
orders within 1 year. Whether BDV or BDV-RNA
is present in human peripheral blood mononuclear
cells remains questionable. Depending on the
virus strain and the host, BDV can induce in
animals a variety of clinical manifestations, from
inapparent infections, behavioral abnormalities,
obesity, fertility problems to fatal neurologic
disease. Animals frequently show behavioral
abnormalities during the course of the disease.
This was very obvious when tree shrews (Tupaia
glis), classified phylogenetically at the root of
primates, were infected with BDV. Here, mainly
disturbances in social behavior and severe apathy
were observed. In contrast, an unequivocal classi-
fication of a definite psychiatric disease with BDV
infections in humans is at present not possible.350 Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997
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To establish the etiologic role of BDV
infections in human psychiatric symptoms, the
following findings must be considered: sympto-
matology of BD in animals is highly variable
depending upon many factors such as age, immune
status, and strain of the animal used for infec-
tion, in addition to the genetic make-up of the
virus; psychiatric symptomatology is nonspecific
(78) even for known genetic causes, which has
represented a major problem for research
investigating known neuropsychiatric disorders
caused by infectious agents. Despite the simi-
larities in BDV infections of animals and
humans, additional future molecular, seroepide-
miologic, and clinical studies will be required to
substantiate the possible contribution of BDV to
the pathophysiology of neuropsychiatric disorders.
This paper is dedicated to Prof. Hermann Becht on
the occasion of his 65th birthday.
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